Clinical Trial Update: Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) [Phase 2]

View source ↗

Summary

Phase 2 trial of TRC105 with bevacizumab in refractory gestational trophoblastic neoplasia terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choriocarcinoma
• Epithelioid Trophoblastic Tumor
• Gestational Trophoblastic Neoplasia
• Placental Site Trophoblastic Tumor

Drugs mentioned

• Bevacizumab (bevacizumab)
• TRC105 (carotuximab)

Snippet

Sponsor: Tracon Pharmaceuticals Inc. | Conditions: Gestational Trophoblastic Neoplasia, Choriocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2019-06-04